Pancreas transplantation is a definitive treatment for type 1 diabetes mellitus, having a 85% success rate of insulin independence at 1 year. 1 Currently, the number of potential recipients for a pancreas transplant exceeds the number of ideal donors. It is well established that successful solid organ transplant outcomes are dependent on careful donor and recipient selection; however, there is increasing pressure to meet the needs of patients on growing waiting lists. To overcome this shortfall, considerable attempts have been made to increase the donor pool. A recent meta-analysis found that donors after circulatory death (DCD) had comparable graft and recipient outcomes to donor after brain death (DBD) pancreas transplantation, 2,3 but these are usually a highly selected cohort of often younger donors with minimal risk of a significant warm ischemic injury. Nevertheless, this suggests that pancreas transplants using carefully selected marginal donors may not have the morbidity often anticipated. A history of donor substance misuse does not negatively impact 10-year graft or patient survival following pancreas transplantation. This is a large national registry analysis with long-term follow-up data and should therefore provide clinicians with reassurance when considering pancreas grafts from substance misuse donors.
Donors who have misused substances, including alcohol, drugs (eg, cannabis, cocaine, heroin), and cigarette smoking are often considered suboptimal due to the potential effects of these substances on the pancreas. These donors are usually young and otherwise ideal, but their organs are often turned down due to uncertainty surrounding the implications of their substance misuse on transplant outcomes. This is reflected in the high decline rate with 13% of otherwise acceptable organs rejected due to "donor history". 4 It is well established that the pancreas is particularly susceptible to damage from alcohol. Long-term alcohol abuse is the primary cause of chronic pancreatitis, accounting for approximately 70%-80% of cases, and a major cause of acute pancreatitis. 5 Clinicians have traditionally been wary of using organs from alcohol abuse donors as there is a perceived increased risk of reperfusion pancreatitis in the recipient. This complication is thought to be associated with increased patient morbidity and decreased pancreas graft survival. 6 Donors who have engaged in illicit drug misuse, particularly intravenous drug use, raise concerns regarding their blood-borne virus status. Most donor-to-recipient disease transmissions are expected and as such pre-emptive therapy and prophylaxis can be used to minimize the impact of transmission. 7 However, despite screening, the transmission of certain diseases (including HIV and HCV) may occur unexpectedly. 8 This remains a rare complication; however, when it does occur the ramifications can be severe with high adverse media interest. 7 The association between smoking and vascular disease is well established. Vascular thrombosis is the main cause of early graft loss following pancreas transplantation, and theoretically, the endothelial activation associated with smoking may be transferred with the organ. We have previously demonstrated that recipient smoking does not negatively impact pancreas transplant outcomes 9 but the impact of donor smoking on the graft has not been previously reported.
Most prior work into the effect of substance abuse on transplant outcomes have focused on the impact of recipient's smoking, illicit drug misuse, and alcohol dependency status, not the donor's history of substance misuse. 10, 11 In kidney transplantation, the outcomes following donor substance misuse have been better outlined. A large retrospective study found that in kidney transplants, a donor history of cigarette smoking had a significant negative impact on both graft and recipient survival, 12 whereas donor IV drug use and donor alcohol dependency were not found to have any significant adverse impact. As smoking, 13 illicit drug misuse, 14 and alcohol abuse 15 are common within the general population, it is important to understand the potential impact this may confer on transplantation outcomes.
The aim of this study was to evaluate whether donor substance misuse has any effect on pancreas transplant outcomes, allowing optimization of donor selection and providing clinicians with the confidence to scientifically assess the risk.
| MATERIAL S AND ME THODS
The UK transplant registry is maintained by the National Health 
| Statistical analysis
Follow-up analysis of the entire cohort was submitted to NHSBT by 
| RE SULTS
Of the 2317 analyzed transplants, 1175 were categorized as substance misusers. Within this cohort, there were 1129 (48.7%) donors with a history of smoking, 163 (7%) donors with a history of alcohol abuse, and 203 (8.7%) donors with a history of drug abuse, Table 1 . There were 327 donors who fell into more than one category of substance misuse.
| Clinical characteristics of donors with a history of substance misuse
Donors with a history of substance abuse represented a distinct population when compared to the normal donor population. The majority of donors who smoked were older (36.3 ± 11.7 vs 32.7 ± 14.4 years, P < 0.001), whereas those donors with a history of drug abuse were more likely to be younger (30.0 ± 9.5 vs 32.7 ± 14.4 years P < 0.001) when compared with non-substance-misusing donors. There was a higher proportion of male donors with a history of alcohol abuse (M:F, 65%:35%) and drug abuse (71.9%:28.1%), P < 0.001. Those donors with a history of any substance misuse were also significantly more likely to be of White, Caucasian ethnic origin, P = 0.02. There was no difference in the type of donation, DBD vs DCD. There was significant variation in donor's cause of death; the donors that smoked were more likely to die from a cerebrovascular accident (63.9% vs 51.5%, P < 0.001) and donors with a history of drug abuse were more likely to die from "other" causes (36.9% vs 28.0%, P < 0.001) examples include out of hospital cardiac arrest, meningitis, or suicide.
| Clinical characteristics of pancreas transplant recipients
With regard to the pancreas transplant recipient population, there were very few differences between the cohorts, Table 2 .
The groups were well matched for age, ethnicity, BMI, mismatch grade, dialysis status, type of pancreas transplant, warm and cold ischemic times. Recipients with their own history of substance misuse (ie, smokers) were not any more likely to be allocated organs from donors with a history of substance abuse. Interestingly, men
were significantly more likely to receive a pancreas graft from a donor with a history of drug or alcohol abuse than women, (alcohol abuse-59.5% vs 40.5%; drug abuse-61.6% vs 38.4%, P < 0.001).
| Univariate analysis of the impact of donor substance misuse on graft & patient survival
Data on graft and patient survival were available for 2073 recipients.
Survival analysis using Kaplan-Meier plots revealed a donor history of substance misuse had no significant impact on 10-year graft survival (GS) or patient survival (PS), Figure 1 , (alcohol abuse GS P = 0.45; PS P = 0.65, drug misuse GS P = 0.93; PS P = 0.08 and smoking GS P = 0.93; PS P = 0.51). Survival analysis was also performed examining the effect that donors with a history of multiple substance misuse (n = 327) may have on outcomes. This again revealed there was no significant impact on graft survival (P = 0.69) or PS (P = 0.12). A sensitivity analysis was performed to evaluate the impact of donor substance misuse on different sub-categories within the pancreas transplant population, for example. transplant type (SPK, PAK, PTA), donor type (DCD vs DBD), and re-transplants. This analysis revealed no effect of donor history of substance misuse on these sub-populations (data not shown).
| Multivariate analysis of the impact of donor substance misuse on graft & patient survival
To understand the impact of donor substance misuse, within the context of the multiple confounding risk factors present in a large retrospective registry analysis, a multivariate analysis was performed. This confirmed that any history of donor substance misuse was not associated with impaired graft of patient survival in pancreas transplantation.
Only traditional markers of poor outcome that is cold ischemic time (P < 0. 
| Postoperative complications
To evaluate the impact of donor substance misuse on the recipient's postoperative course, the rate of a number of common complications was compared between groups. These data were taken from the 3-month follow-up report submitted to NHSBT by transplant coordinators. Follow-up data were not routinely collected for the early cohort of friend. This collateral information may be inaccurate as family members may not be aware of all risk-taking behaviors. Another difficulty associated with data capture in this circumstance is the confusing terminology. By using an inclusive, "broad-brush" approach to incorporate the entire spectrum of substance misuse and standardizing terminology to cover all variations, this may have resulted in a dilution of the actual effect size. For example, when comparing intravenous drug abuse versus casual cannabis misuse it might be assumed that one risk-taking behavior is likely to have a more significant impact on a donor's health than the other. However, in our analysis these two situations were both coded as the same variable. Nonetheless, this approach was necessary to facilitate the analysis and is a standard methodology when dealing with large retrospective datasets. Also, the likelihood is, these two opposing difficulties with data collection have negated each other, and therefore, we feel these findings can be reflected as an accurate representation of the donor population.
| D ISCUSS I ON
The sensitivity analysis also confirmed these findings were consistent when focussing on specific sub-populations within the whole registry analysis.
This account is verified by the multivariate analysis which suggested that cold ischemic time, increasing donor age, increasing recipient BMI, PTA, and PAK pancreas grafts had a significant impact, with decreased graft survival. Increased recipient age and PTA grafts had a negative correlation with patient survival. These findings are well documented in previous literature. 16 The primary concern many clinicians will have with accepting organs from substance misuse donors; particularly, IVDU donors are the increased risk of viral transmission. A previous study published by one of our authors has investigated this aspect in significant detail using this same UK registry cohort of pancreas recipients but also including recipients of the other solid organs from the same donor. The study investi- Historical data suggest that Hepatitis C has a negative impact on both patient and graft survival. 18 Rapid advancements in direct-acting antivirals (DAAs) means interferon-free therapy with higher cure rates and less adverse side effects are now available. These have been used to enable kidney organ transplantation from HCV positive donors to HCV negative recipients who were treated with DAAs, preventing disease transmission. 19 These affiliated lines of research could mean donor IVDU is no longer a barrier to transplantation.
Currently in the UK, blood-borne virus screening of deceased donors relies on serology rather than nucleic acid testing (NAT).
Uncertainty regarding the donor's serology may contribute to clinicians' apprehension to utilize functionally good pancreata from donors with a history of drug misuse. NAT can significantly reduce the "window period" from infection to detection and decrease the risk of transmitting disease from a serologically negative donor. 20 However, NAT is costly and can be logistically challenging. 21 A change in policy that advocates funding for routine NAT in high-risk donors may increase the utilization of organs. 22 Interestingly, the recipients who received a graft from a donor with a history of smoking were significantly more likely to go on to develop an anastomotic leak. Fortunately, this is did not impair longterm graft or patient survival. The underlying reason for more leaks may be explained by the well-established effect that smoking has on wound healing and the microvasculature, resulting in the donor duodenum being more susceptible to dehiscence. This is a well-reported phenomenon in colorectal surgery. 23 We have also shown that donors with a history of smoking were likely to be older but this did not have a compounding effect on graft or patient survival. When adding the variables into the multivariate model, donor age represented a significant hazard impairing graft survival, whereas smoking status did not. This demonstrates that the negative impact of donor age holds true in the model irrespective of donor smoking status and other potentially confounding variables.
Equally, the nonsignificant impact of donor smoking status holds true when all other potentially confounding variables (donor age included) remain constant. The interaction term between donor age and smoking status was also nonsignificant revealing there is no compounding effect on graft survival when both of these variables are present.
The overall reported incidence of postoperative complications ( difficult to account for without considering statistical methods of imputation which were not undertaken for this study.
An unusual finding from this study has been that men were more likely than women to receive pancreas grafts from "risky" donors with a history of alcohol abuse or drug misuse. This phenomenon is difficult to understand but may be the result of a subconscious gender bias. There have been previous studies that reported clinician's decisions regarding organ allocation and listing for transplant are subject to socioeconomic and racial bias 25, 26 ; however, there is very limited data about the effect of recipient's gender on these decisions.
Our findings are consistent with those of a previous, much smaller study, which found no impact of donor substance misuse on early pancreas graft failure. 27 Whilst this is reassuring, the other study was based on a single center experience, with a cohort of 62 donors and no long-term follow-up. Having used data from the UK registry, our findings have greater statistical power, wider applicability, and the potential for greater clinical impact.
The majority of patients receiving a pancreas transplant had a simultaneous kidney transplant. However, our findings are contrary to those found in kidney transplants, with donor smoking having a significant effect on patient outcomes in kidney allografts. 12 It is unclear why this difference exists; however, that study utilized the American UNOS registry for analysis with donors from prior to 1999, whilst our study is a more contemporaneous UK registry analysis.
Therefore, differences in the donor population groups may account for this discrepancy.
This study has been conducted using data from a large registry series, with long-term follow-up of 10 years. Consequently, it is very reassuring and convincing to see such positive outcomes.
Decisions will still have to be taken on an organ-by-organ basis, weighing up risks and benefits for that particular recipient and collectively considering other donor factors. It is important that these decisions are taken during a process of shared decision making, with the patient fully informed of the risks and benefits of the individual grafts. Our study provides clinicians and surgeons with the ability to explain the evidence base regarding these allocation decisions and more confidence in the utility of this group of marginal donors. 
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